Sattva Sukun Lifecare Ltd (539519)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Sattva Sukun's revenue was ₹0.6 Cr (-47.5% year on year, -92.5% on the previous quarter), and net profit ₹-0.2 Cr (against a profit a year earlier); the operating margin was -37.5%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹0.6 | -47.5% | -92.5% |
| Operating profit | ₹-0.2 | to loss | loss narrowed |
| Net profit | ₹-0.2 | to loss | loss narrowed |
| EPS (₹) | 0.00 | -100.0% | loss narrowed |
| Operating margin | -37.5% | — | — |
📢 Recent Corporate Announcements
Tavexia Lifecare Limited has announced the acquisition of a 60% controlling equity stake in Meyonex Pharmaceuticals Limited for ₹67.19 Crore. The transaction will be executed via cash subscription of 2,09,97,180 fresh equity shares at ₹32 per share, granting Tavexia access to a manufacturing unit in MIDC Tarapur, Maharashtra. The ₹67.19 Crore transaction is massive relative to Tavexia's scale, exceeding 200% of its TTM revenue of ₹32 Crore and net worth of ₹43 Crore. To finance the purchase, the company plans to initiate strategic fund-raising via equity or convertible instruments.
- Acquiring a 60% controlling stake in Meyonex Pharmaceuticals Limited for ₹67.19 Crore
- Subscription of 2,09,97,180 fresh equity shares at an issue price of ₹32 per share
- Deal value represents ~210% of TTM revenue (₹32 Cr) and exceeds net worth (₹43 Cr)
- Target brings an operational manufacturing base in MIDC Tarapur, Maharashtra
- Financing planned via fresh strategic fund-raising through equity or convertible instruments
Tavexia Lifecare's Board approved the acquisition of a 60% controlling stake in Meyonex Pharmaceuticals Limited for ₹67.19 crore via cash subscription. The transaction involves subscribing to 2,09,97,180 fresh equity shares at ₹32 per share, giving Tavexia access to a manufacturing facility in MIDC Tarapur, Maharashtra. The deal size of ₹67.19 crore is massive relative to Tavexia's TTM revenue of ₹32 crore and net worth of ₹43 crore. To fund the purchase, the company plans to raise capital through equity or convertible instruments.
- Acquiring 60% controlling equity stake in Meyonex Pharmaceuticals Limited
- Total deal consideration of ₹67.19 Crore via cash subscription
- Subscribing to 2,09,97,180 fresh equity shares at an issue price of ₹32 per share
- Gains manufacturing operations located in MIDC Tarapur, Maharashtra
- Deal value represents ~210% of TTM revenue (₹32 Cr) and ~156% of net worth (₹43 Cr)
Tavexia Lifecare's Board approved the acquisition of a 60% controlling stake in Meyonex Pharmaceuticals Limited for an all-cash consideration of ₹67.19 crore. The transaction involves subscribing to 2,09,97,180 fresh equity shares of Meyonex at ₹32 per share. To finance this acquisition, which significantly exceeds Tavexia's TTM revenue of ₹32 crore and net worth of ₹43 crore, the Board approved an in-principle fundraise via equity, warrants, or debt. Meyonex reported a turnover of ₹10.79 crore in FY25.
- Proposed acquisition of 60% post-allotment equity stake (2,09,97,180 shares) in Meyonex Pharmaceuticals Limited
- Total cash consideration fixed at ₹67,19,09,760 at an issue price of ₹32 per share
- In-principle approval to raise funds via preferential issue, rights issue, or debt to fund the deal
- Target entity reported FY25 turnover of ₹10,79,21,500 compared to ₹13,32,07,500 in FY24
Tavexia Lifecare's Board approved the acquisition of a 60% controlling stake in Meyonex Pharmaceuticals Limited for an all-cash consideration of ₹67.19 crore. The transaction involves subscribing to 2,09,97,180 fresh equity shares of Meyonex at ₹32 per share. To finance this acquisition, which significantly exceeds Tavexia's TTM revenue of ₹32 crore and net worth of ₹43 crore, the Board approved an in-principle fundraise via equity, warrants, or debt. Meyonex reported a turnover of ₹10.79 crore in FY25.
- Proposed acquisition of 60% post-allotment equity stake (2,09,97,180 shares) in Meyonex Pharmaceuticals Limited
- Total cash consideration fixed at ₹67,19,09,760 at an issue price of ₹32 per share
- In-principle approval to raise funds via preferential issue, rights issue, or debt to fund the deal
- Target entity reported FY25 turnover of ₹10,79,21,500 compared to ₹13,32,07,500 in FY24
Tavexia Lifecare has scheduled a Board meeting on October 7, 2026, to deliberate on the proposed acquisition of up to 60% equity in Meyonex Pharmaceuticals Limited. This follows an initial approval granted on September 7, 2026, which authorised preliminary evaluation, valuation, and due diligence. For a micro-cap company with a market cap of approximately ₹1 crore and TTM revenue of ₹32 crore, acquiring a controlling stake could significantly alter its operational footprint. Additionally, the trading window has been closed from September 30, 2026, ahead of the half-year results.
- Board meeting scheduled for October 7, 2026, to discuss proposed acquisition
- Target is up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited
- Follows earlier board approval dated September 7, 2026, for due diligence and valuation
- Trading window closed from September 30, 2026, until 48 hours after H1 results
Tavexia Lifecare Limited has announced its strategic entry into the pharmaceutical business as an additional growth vertical alongside its existing lifecare operations. The company plans to explore opportunities across pharma products, APIs, intermediates, specialty chemicals, and nutraceuticals. However, the announcement does not disclose any concrete capex commitments, manufacturing locations, or commercial timelines. This comes against a micro-cap financial base with TTM revenue of ₹32 Cr and a market cap of ₹1 Cr.
- Announced entry into pharmaceuticals covering APIs, intermediates, specialty chemicals, and nutraceuticals
- Cites Indian pharma market size at ~US$60 billion, projected to reach ~US$130 billion by 2030
- Highlights Indian pharma exports at ~US$30.47 billion in FY2024-25
- Specific capital outlay and operational timelines were not disclosed in the filing
Sattva Sukun Lifecare Limited has received approval from the Ministry of Corporate Affairs (MCA) and BSE Limited to change its name to Tavexia Lifecare Limited. The Central Processing Centre of the MCA issued a fresh Certificate of Incorporation on August 14, 2026. The company operates in the distribution sector with a TTM revenue of Rs 32 Cr and a market capitalization of Rs 1 Cr. The name change is a corporate rebranding step and does not alter the company's underlying assets, liabilities, or business operations.
- Name changed from Sattva Sukun Lifecare Limited to Tavexia Lifecare Limited
- MCA issued fresh Certificate of Incorporation on August 14, 2026
- BSE Limited has approved the application for the corporate name change
- Original company incorporation name was Mayukh Commercial Limited under CIN L51219MH1980PLC329224
Sattva Sukun Lifecare approved its Q1 FY27 financial results and provided an update on its July 2025 Rights Issue. The company raised Rs 19.16 crore and has successfully utilized Rs 18.92 crore (approx. 98.7%) as of June 30, 2026. A significant portion of the funds, Rs 11.94 crore, was directed toward strategic investment in its subsidiary, PavaPuri Export Private Limited. Despite the large fund deployment, the company remains a micro-cap with a market capitalization of only Rs 1 crore and a low promoter holding of 6.4%.
- Raised Rs 19.16 crore through a Rights Issue completed on July 7, 2025
- Utilized Rs 18.92 crore of the total proceeds as of the quarter ended June 30, 2026
- Invested Rs 11.94 crore into subsidiary M/s PavaPuri Export Private Limited for strategic growth
- Allocated Rs 3.00 crore for business expansion, including acquisition of office premises, factory, and land
- Reported zero deviation in the use of funds compared to the modified objects of the issue
Sattva Sukun Lifecare (formerly Mayukh Dealtrade) approved its Q1 FY27 results and reviewed the utilization of Rs 19.16 Cr raised via a Rights Issue in July 2025. As of June 30, 2026, the company has deployed Rs 18.91 Cr, representing 98.7% of the total funds raised. A significant portion of the proceeds, Rs 11.94 Cr, was directed toward a strategic investment in its subsidiary, PavaPuri Export Private Limited, while Rs 3.00 Cr was used for business expansion including office and factory premises.
- Rs 19.16 Cr total funds raised via Rights Issue on July 7, 2025.
- Rs 18.91 Cr total funds utilized as of June 30, 2026, leaving a balance of Rs 0.24 Cr.
- Rs 11.94 Cr invested in subsidiary M/s PavaPuri Export Private Limited, the largest single allocation.
- Rs 3.00 Cr deployed for business expansion including acquisition of office premises, factory, and land.
- Original fund-raising target of Rs 49.50 Cr was significantly scaled down to Rs 19.16 Cr.
Sattva Sukun Lifecare (formerly Mayukh Dealtrade) has scheduled a board meeting for August 4, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. Crucially, the board will also review the statement of deviation or variation regarding the use of proceeds from its Rights Issue. This comes as the company reported a significant revenue jump to Rs 32.25 Cr in FY26 but struggled with a negative operating margin of -15.91%. Investors should remain cautious given the company's micro-cap status (Rs 1 Cr) and low promoter holding of 6.39%.
- Board meeting scheduled for August 4, 2026, to approve Q1 FY27 results.
- Review of fund utilization from the Rights Issue as per Regulation 32 of SEBI LODR.
- Trading window for designated persons has been closed since April 1, 2026.
- Company reported TTM revenue of Rs 32 Cr against a tiny market cap of just Rs 1 Cr.
- Promoter holding remains stagnant and low at 6.39% as of June 2026.
Sattva Sukun Lifecare Ltd has issued a corrigendum to its Extra-Ordinary General Meeting (EOGM) notice scheduled for July 22, 2026. The primary agenda is to change the company's name to Tavexia Lifecare Limited for branding purposes. The corrigendum includes a required Chartered Accountant certificate confirming compliance with SEBI Regulation 45, noting that more than one year has passed since the previous name change on December 12, 2024. The company maintains that its core business in lifecare and wellness remains unchanged.
- Proposed name change from Sattva Sukun Lifecare Limited to Tavexia Lifecare Limited
- EOGM scheduled for July 22, 2026, at 02:00 PM via video conferencing
- Last name change from Mayukh Dealtrade Limited occurred on December 12, 2024
- Corrigendum issued to address BSE queries regarding the in-principle application for name change
- Company confirms no change in principal business activity or legal status
Sattva Sukun Lifecare Ltd has issued a corrigendum to its Extra-Ordinary General Meeting (EOGM) notice scheduled for July 22, 2026. The board has approved a proposal to change the company's name to 'Tavexia Lifecare Limited' or 'Trumaxa Lifecare Limited' to better reflect its branding strategy. This follows a previous name change from Mayukh Dealtrade Limited in December 2024. The company confirmed that the change does not involve a shift in business activity, as it remains focused on the lifecare and wellness sector.
- EOGM scheduled for July 22, 2026, at 2:00 PM to approve the name change via special resolution.
- Last name change occurred on December 12, 2024, satisfying the SEBI requirement of a 1-year gap between name changes.
- The proposed name change is purely for branding and does not involve a change in the principal business activity.
- A revised Chartered Accountant certificate was issued on July 17, 2026, to comply with BSE queries regarding Regulation 45 of SEBI LODR.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
